|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Security deposits and leasehold improvements | ||||||||||||||||||||
| Current portion of security deposits | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Noncurrent portion of security deposits and leasehold improvements | ||||||||||||||||||||
| Security deposits | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Security deposits and leasehold improvements | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS'(DEFICT) EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| NONCURRENT LIABILITIES: | ||||||||||||||||||||
| Noncurrent portion of operating lease liabilities | ||||||||||||||||||||
| Clinical holdback - long-term portion | ||||||||||||||||||||
| Total noncurrent liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS' (DEFICIT) EQUITY: | ||||||||||||||||||||
| Common stock, $0.0001 par value; 250,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 144,300,674 shares issued and outstanding as of September 30, 2025 and 137,228,741 shares issued and outstanding as of December 31, 2024 | ||||||||||||||||||||
| Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30 and December 31, 2024; 0 shares issued and outstanding as of September 30 and December 31, 2024 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' (deficit) equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY |
Loading...
